



## HE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Rolf Gericke et al.

Examiner: POWERS, Fiona

Serial No.: 10/574,781

Group Art Unit: 1626

Filed: APRIL 6, 2006

Confirmation Number: 2544

Title: ACYLHYDRAZONE DERIVATIVES AND THE USE THEREOF IN THE

INHIBITION, REGULATION AND/OR MODULATION OF KINASE SIGNAL

TRANSDUCTION

## RESPONSE TO RESTRICTION REQUIREMENT

MAIL STOP AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Restriction Requirement dated July 18, 2007, Applicants hereby elect, with traverse, Group I (claims 1–6, 15, and 16) drawn to a compound of Formula I, composition(s) and/or kit(s) thereof.

In response to the Election of Species Requirement, Applicants hereby elect, with traverse, the compound N-(4-hydroxy-2-methoxybenzylidene)-(3-hydroxyphenyl)-acetohydrazide, as recited in Example 1 at page 26 of the originally filed specification. See also, the subject matter of Applicants' instant claim 5.

At page 2 of the open Office Action, the Examiner alleges that the inventions listed in Groups I and II do not relate to a single general inventive concept because they allegedly lack the same or corresponding technical feature. Applicants respectfully disagree with this contention. All the claims in the application involve related subject matter, for example, a compound of Formula I, composition(s) and kit(s) thereof, and use of such compounds, compositions and/or kits. Moreover, Applicants' disclosed species clearly possess unity of invention under PCT Rule 13.1. For example, see the disclosure contained in Examples 1 and 2 of the specification, as originally filed.

It is respectfully submitted that, in view of the totality of the disclosure contained

in the instant specification, Applicants' claims relate to a single inventive concept. Moreover, the Office Action has not demonstrated that an undue searching burden would be required to examine all groups and certainly not to examine at least more than one of the groups. "If search and examination of an entire application can be made without serious burden, the examiner <u>must</u> examine it on the merits, even though it includes claims to independent or distinct invention." (Emphasis added.) See, M.P.E.P. §803. Accordingly, the Requirement for Restriction should be withdrawn.

Should the Restriction Requirement still be maintained, Applicants will seek reentry of any withdrawn claims once allowable subject matter has been determined.

No fees are believed to be due with this response; however, the Commissioner is hereby authorized to charge any fees associated with this response to Deposit Account No. 13-3402.

Respectfully submitted,

Anthony J. Zelano, Reg. No. 27,969

Attorney for Applicant(s)

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza 1, Suite 1400 2200 Clarendon Boulevard Arlington, Virginia 22201 Telephone: (703) 243-6333 Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-3158

Date: August 3, 2007